Indications and uses
For the treatment of vulvovaginitis caused by Candida albicans . (See CLINICAL PHARMACOLOGY .)
For the treatment of vulvovaginitis caused by Candida albicans . (See CLINICAL PHARMACOLOGY .)
One applicatorful (about 6 g) intravaginally once or twice daily. Improvements in symptoms should occur within a few days, but treatment should be continued for a period of 30 days. Douching with a suitable solution before insertion may be recommended for hygienic purposes.
AVC CREAM® (sulfanilamide) 15%
AVC® (sulfanilamide)
Cream
AVC® is a preparation for vaginal administration for the treatment of Candida albicans infections and available in the following form:
AVC Cream
Each tube contains:
Sulfanilamide.............................................................................................15.0%
in a water-miscible, non-staining base made from lactose, propylene glycol, stearic acid, diglycol stearate, methylparaben, propylparaben, trolamine, and water; buffered with lactic acid to an acid pH of approximately 4.3.
Sulfanilamide is an anti-infective agent. It is p-amino-benzenesulfonamide with the chemical structure:

Sulfanilamide occurs as a white odorless crystalline powder with a slightly bitter taste and sweet aftertaste. It is slightly soluble in water, alcohol, acetone, glycerin, propylene glycol, hydrochloric acid, and solutions of potassium and sodium hydroxide. It is practically insoluble in chloroform, ether, benzene, and petroleum ether.
Sulfanilamide has been a useful ingredient of vaginal formulations for about four decades. It blocks certain metabolic processes essential for the growth of susceptible bacteria. In AVC, the sulfanilamide is in a specially compounded base buffered to the pH (about 4.3) of the normal vagina to encourage the presence of the normally occurring Döderlein’s bacilli of the vagina.
The use of AVC for the treatment of vulvovaginitis caused by Candida albicans is supported by three clinical investigations. The three studies show AVC with sulfanilamide to be significantly more effective (p ≤ 0.01) than placebo as follows:
In Study I, the ratio of effectiveness was 71% for the AVC with sulfanilamide versus 49% for placebo with 30 days of treatment;
In Study II, the percentages were 48% and 24%, respectively, with 15 days of treatment;
In Study III, the percentages were 66% versus 33%, respectively, with 30 days of treatment.
For the treatment of vulvovaginitis caused by Candida albicans. (See CLINICAL PHARMACOLOGY.)
AVC should not be used in patients known to be sensitive to this product or to the sulfonamides.
Because sulfonamides are absorbed from the vaginal mucosa, the usual precautions for oral sulfonamides apply. Patients should be observed for skin rash or evidence of systemic toxicity, and if these develop, the medications should be discontinued.
Deaths associated with administration of oral sulfonamides have reportedly occurred from hypersensitivity reactions, agranulocytosis, aplastic anemia, and other blood dyscrasias.
Goiter production, diuresis, and hypoglycemia have reportedly occurred rarely in patients receiving oral sulfonamides. Cross-sensitivity may exist with these agents. Rats appear to be especially susceptible to the goitrogenic effects of sulfonamides, and long-term administration has reportedly produced thyroid malignancies in this species.
Vaginal applicators or inserters should be used with caution after the seventh month of pregnancy.
The doctor should advise the patient that in the event unusual local itching and burning occur, or other unusual symptoms develop, medication should be discontinued and not restarted without further consultation.
Drug interactions have not been documented with AVC.
No data are available on long-term potential of AVC for carcinogenicity, mutagenicity, or impairment of fertility in animals or humans.
Teratogenic Effects. Animal reproductive studies have been conducted with sulfonamides, including sulfanilamide (see below). It is not known whether AVC can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. AVC should be given to a pregnant woman only if clearly needed.
Sulfonamides, including sulfanilamide, readily pass through the placenta and reach fetal circulation. The concentration in the fetus is from 50-90% of that in the maternal blood and if high enough, can cause toxic effects. The safe use of sulfonamides, including sulfanilamide, in pregnancy has not been established. The teratogenic potential of most sulfonamides has not been thoroughly investigated in either animals or humans. However, a significant increase in the incidence of cleft palate and other bony abnormalities of offspring has been observed with certain sulfonamides of the short-, intermediate- and long-acting types (including sulfanilamide) when given to pregnant rats and mice at high oral doses (seven to 25 times the human therapeutic oral dose.)
Sulfanilamide should be avoided in nursing mothers because absorbed sulfonamides will appear in maternal milk and have caused kernicterus in the newborn. Because of the potential for serious adverse reactions in nursing infants from sulfonamides, a decision should be made whether to discontinue nursing or to discontinue the drug.
Safety and effectiveness of AVC in pediatric patients have not been established.
To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc. at 1-877-999-8403 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
ADVERSE REACTIONS
Local sensitivity reactions such as increased discomfort or a burning sensation have occasionally been reported following the use of topical sulfonamides. With the use of AVC Cream, sensitivity reactions (only local) were reported for 0.2% of the investigational patients.
Treatment should be discontinued if either local or systemic manifestations of sulfonamide toxicity or sensitivity occur.
Tolerance, abuse, or dependence with AVC have not been reported.
There have been no reports of accidental overdosage with AVC.
The acute oral LD50 of sulfanilamide is 3700-4200 mg/kg in mice.
The minimum human lethal dose of AVC has not been established.
It is not known if AVC is dialyzable.
One applicatorful (about 6 g) intravaginally once or twice daily. Improvements in symptoms should occur within a few days, but treatment should be continued for a period of 30 days.
Douching with a suitable solution before insertion may be recommended for hygienic purposes.
AVC Cream
NDC 0037-6631-04 4 oz tube with applicator
Store at room temperature, below 86°F.
Protect from cold.
Product darkens with age. Potency is maintained throughout labeled shelf life when stored as directed.
This leaflet provides a summary of the important information about AVC Cream. You can get more information by calling the toll free number (1-877-999-8403).
Distributed by:
Meda Pharmaceuticals
Somerset, New Jersey 08873-4120
©2018 Mylan Specialty L.P.
AVC is a registered trademark of Meda Pharma S.A.R.L., a Mylan company.
141016
IN-663103-02
Rev. 6/2018
NDC 0037-6631-04 Rx only
4 ounces vaginal cream with applicator
AVC® CREAM
(sulfanilamide) 15%
Contains: sulfanilamide 15% in a water-miscible, non-staining base made from lactose,
propylene glycol, stearic acid, diglycol stearate, methylparaben, propylparaben, trolamine,
and water; buffered with lactic acid to an acid pH of approximately 4.3.
Usual dose: 1 applicatorful (about 6 g) intravaginally once or twice daily. Improvements in
symptoms should occur within a few days, but treatment should be continued for a
period of 30 days.
How to use cream applicator:



It is recommended that a pad be used to protect clothing.
Storage: Store at room temperature (below 86ºF).
Protect from cold.
Directions for use of applicator are printed under tear-away panel of carton.
Rx only.
Storage: Store at room temperature (below 86ºF).
Protect from cold.
Product darkens with age. Potency is maintained throughout labeled shelf life when stored as directed.
117404
Distributed by:
MEDA PHARMACEUTICALS®
Somerset, New Jersey 08873-4120
© 2018 Mylan Specialty L.P.
AVC is a registered trademark of Meda Pharma S.A.R.L., a Mylan
company
UC-663103-03
Rev. 5/2018

| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0037-6631-04 | GM - Gram | 0037-6631 | b5b3179a-f1c1-4c91-b5c2-879630f01f78 | 1 | 2015-01-05 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| SULFANILAMIDE | ACTIVE INGREDIENT | 21240MF57M | 1 | |
| SULFANILAMIDE | ACTIVE MOIETY | 21240MF57M | 1 | |
| LACTIC ACID | INACTIVE INGREDIENT | 33X04XA5AT | 1 | |
| LACTOSE MONOHYDRATE | INACTIVE INGREDIENT | EWQ57Q8I5X | 1 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| PEG-2 STEARATE | INACTIVE INGREDIENT | 94YQ11Y95F | 1 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 1 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | 1 | |
| TROLAMINE | INACTIVE INGREDIENT | 9O3K93S3TK | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0037-6631 | 0037-6631-04 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| SULFANILAMIDE | 21240MF57M | ACTIB |
| LACTOSE MONOHYDRATE | EWQ57Q8I5X | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| STEARIC ACID | 4ELV7Z65AP | IACT |
| PEG-2 STEARATE | 94YQ11Y95F | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
| TROLAMINE | 9O3K93S3TK | IACT |
| WATER | 059QF0KO0R | IACT |
| LACTIC ACID, UNSPECIFIED FORM | 33X04XA5AT | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION / INTRAMUSCULAR | 150 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | SOLUTION / TOPICAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / RECTAL | 1214 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRALESIONAL | 0.02 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / IRRIGATION | 2 %w/v | ||
| TROLAMINE | TROLAMINE | 9O3K93S3TK | POWDER / TOPICAL | 0.02 mg/mg | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | INJECTION / INTRAVENOUS | 2232 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 690 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 520 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / OPHTHALMIC | 0.75 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / SUBCUTANEOUS | 1.4 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION/ DROPS / OPHTHALMIC | 0.05 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / TOPICAL | 1800 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / TOPICAL | 420 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / EPIDURAL | 1 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / NASAL | 26 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | POWDER, FOR SUSPENSION / ORAL | 75 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CLOTH / TOPICAL | 0.03 mg/mg | ||
| TROLAMINE | TROLAMINE | 9O3K93S3TK | SOLUTION / TOPICAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | EMULSION / TOPICAL | 0.2 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / NASAL | 250 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SYRUP / ORAL | 40 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / TOPICAL | 216 mg | ||
| TROLAMINE | TROLAMINE | 9O3K93S3TK | GEL, METERED / TRANSDERMAL | 14 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | AEROSOL, FOAM / VAGINAL | 4 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / VAGINAL | 750 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TAMPON / VAGINAL | 62.1 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CREAM / VAGINAL | 1225 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | OINTMENT / TOPICAL | 15 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LIQUID / RESPIRATORY (INHALATION) | 10 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / AURICULAR (OTIC) | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | ELIXIR / ORAL | 9306 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / NASAL | 5 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SWAB / TOPICAL | 34.6 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / NASAL | 140 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / TOPICAL | 5148 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | AEROSOL, FOAM / TOPICAL | 0.16 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CONCENTRATE / ORAL | 2.5 mg/5ml | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | AEROSOL, FOAM / TOPICAL | 11 mg | ||
| TROLAMINE | TROLAMINE | 9O3K93S3TK | SOLUTION / NASAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / DENTAL | 2 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SHAMPOO / TOPICAL | 0.03 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM / BUCCAL | 1.48 mg | ||
| LACTIC ACID | LACTIC ACID | 33X04XA5AT | CREAM / VAGINAL | 0.81 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / RECTAL | 0.02 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | AEROSOL, FOAM / TOPICAL | 0.04 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION/ DROPS / OPHTHALMIC | 0.01 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / IONTOPHORESIS | 0.1 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | GEL / TOPICAL | 24 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | TABLET / ORAL | 0.2 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SPRAY / NASAL | 0.2 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CREAM / TOPICAL | 76000 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 19 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / ORAL | 1 mg/1ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT, AUGMENTED / TOPICAL | 714 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / VAGINAL | 6.4 %w/w | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | CAPSULE / ORAL | 90 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, DELAYED RELEASE / ORAL | 2313 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LOTION / TOPICAL | 3392 mg | ||
| TROLAMINE | TROLAMINE | 9O3K93S3TK | SPRAY / NASAL | NA |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N006530-003 | AVC | SULFANILAMIDE | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | |
| N006530-004 | AVC | SULFANILAMIDE | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | N006530-003 | AVC | 15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CREAM / VAGINAL | RLD | 1987-01-27 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N006530-003 | AVC | 15% | CREAM / VAGINAL | RLD | 1987-01-27 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N006530-003 | AVC | 15% | CREAM / VAGINAL | RLD | 1987-01-27 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | N006530-003 | AVC | 15% | CREAM / VAGINAL | RLD | 1987-01-27 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | N006530-003 | AVC | 15% | CREAM / VAGINAL | RLD, RS | 1987-01-27 | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N006530-004 | AVC | 1.05GM | SUPPOSITORY / VAGINAL | 1987-01-27 | 74a2ff9319b5… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 7e724bec-38d4-41ae-ba9f-c2d29573160a | d344f475-1bf2-4aaf-aae3-0cd0be4995d1 | 2018-06-13 | Adverse reactions | d344f475-1bf2-4aaf-aae3-0cd0be4995d1 |
Adverse event summaries are temporarily unavailable. Other product information remains available.